Share with Your Friends

Heart, Lung and Circulation (2018) 27, 276–279 1443-9506/04/$36.00

https://doi.org/10.1016/j.hlc.2017.10.007

POSITION STATEMENT

Update on the Diagnosis and Management of Hypertrophic Cardiomyopathy$

Christopher Semsarian, AM, MBBS, PhD, MPH, FAHMS, FRACP, FRCPA a,b*, on behalf of the CSANZ Genetics Council Writing Group

*Agnes Ginges Centre for Molecular Cardiology, Centenary Institute and University of Sydney, Sydney, NSW, Australia

*Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia

This standard of practice document briefly outlines the current approach to the diagnosis and management of hypertrophic cardiomyopathy (HCM). The supporting levels of evidence are reported in both the American Heart Association HCM guidelines [1] and the European Society of Cardiology HCM guidelines [2]. There is also a detailed recent review of HCM for further reference [3]. Since the last CSANZ HCM guidelines in 2011, the main changes relate to emerging sudden death risk factors such as the amount of myocardial fibrosis, the development of an HCM Risk Score, and more careful consideration of cascade genetic testing in asymptomatic relatives without an HCM phenotype.

 

Clinical Characteristics of HCM

Definition and Prevalence

Hypertrophic cardiomyopathy (HCM) is a primary cardiac disorder characterised by hypertrophy, usually of the left ventricle, in the absence of other loading conditions, such as aortic stenosis, hypertension or thyroid disease. Although previously thought of as a rare disorder, recent population-based clinical studies suggest the prevalence of the condition to be as high as 1 in 200 in the general population [4] making HCM the commonest known cardiovascular genetic disorder known.

Clinical Presentation

Hypertrophic cardiomyopathy is inherited as an autosomal dominant disorder with variable penetrance. This means affected individuals are heterozygous and offspring of affected individuals have a 50% risk of inheriting the gene

mutation, with males and females equally at risk. Patients with HCM can range in presentation from minimal or no symptoms and have a benign, asymptomatic course, to the development of the most serious complications including heart failure and sudden death. HCM is a common structural cause of sudden cardiac death in individuals aged less than 35 years, including competitive athletes. The pathophysiology of HCM is complex and is reflected in the diversity of clinical features. Individuals with HCM can have a variety of symptoms including chest pain, which may be typical of angina, symptoms related to pulmonary congestion, i.e. dyspnoea, fatigue, orthopnea, and paroxysmal nocturnal dyspnoea, impaired consciousness, i.e. syncopal and pre-syncopal episodes, and palpitations [3].

Clinical Diagnosis

Clinical examination features of HCM include the characteristic ‘‘jerky” rapidly rising pulse and prominent left ventricular impulse, and an apical systolic murmur, which increases with the Valsalva manoeuvre and is related to dynamic obstruction. There is frequently a fourth heart sound. The 12-lead electrocardiogram (ECG) may show abnormalities including voltage criteria for left ventricular hypertrophy, T-wave inversion and Q waves. The echocardiogram remains the investigation which most reliably confirms the diagnosis of HCM and which provides detailed information about the distribution and severity of hypertrophy, the left ventricular cavity size, assessment of left ventricular systolic and diastolic function, left ventricular outflow tract obstruction and mitral regurgitation. Hypertrophic cardiomyopathy is usually recognised by a maximal left ventricular wall thickness 215 mm in adults (13–14 mm is considered borderline unless there is a definite family

 

$ This document has been endorsed by the CSANZ Genetic Council.

$$ This position statement was reviewed by the Quality Standards Committee and ratified at the CSANZ Board meeting held on Friday, 25 November 2016.

*Correspondence to: Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, Locked Bag 6, Newtown, NSW 2042, Australia. Email: c.semsarian@centenary.org.au

© 2017 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.


Hypertrophic Cardiomyopathy                                                                                                                                                                     277

 

history of HCM). Other investigations that may be helpful in confirming the diagnosis or in establishing ‘‘risk of sudden death” profile include exercise testing (with or without echocardiography or myocardial perfusion scanning), ambulatory Holter monitoring, and a history of cardiac events in other family members.

When considering the diagnosis of HCM, a number of ‘‘HCM phenocopies” may also need to be considered, particularly when the hypertrophy is more concentric rather than asymmetric. These include infiltrative disorders such as Fabry disease and amyloidosis, as well as glycogen and lysosomal storage diseases.

Most recently, cardiac magnetic resonance (CMR) imaging has emerged as an important investigation in further defining the extent and severity of both cardiac hypertrophy and fibrosis. The diagnostic criteria for HCM remain the same as for echocardiography, i.e. maximal left ventricular wall thickness 215 mm in adults. The main advantages of CMR imaging over echocardiography relate to quantification of fibrosis using LGE, as well as assessment of areas of the heart not as well imaged by echocardiography, namely apical HCM. Rarely, cardiac biopsies are obtained and may show the classical histopathological features of HCM, including myofibre disarray, myocyte hypertrophy and interstitial fibrosis, although such findings are usually not identified until post-mortem.

Risk Stratification for Sudden Cardiac Death

The issue from the clinicians’ perspective is how does one determine who is at highest risk of sudden death. The table below summarises the current factors considered important in evaluating which individuals with HCM are at highest risk of sudden death. Most clinicians would recommend ICD therapy if any one of the five major risk factors is present, although recent debate has focussed on whether at least two risk factors are required. The other risk factors listed in Table 1 have been shown in studies in smaller cohorts of patients to play an incremental role in evaluating risk of sudden death, including recent early evidence that the amount of late gadolinium enhancement (LGE >15% of left ventricular myocardium) on CMR imaging may also be an important risk factor. Clearly, many patients have some of the minor risk factors and so the decision regarding

prophylactic ICD therapy is difficult. In this case, a combination of clinical judgement and the desires of the individual patient need to be considered.

Most recently, the HCM Risk Score [5] has been established which calculates risk based on a number of variables in addition to the risk factors outlined in Table 1, including LVOT gradient, left atrial size, and age at evaluation. This risk prediction model then calculates the 5-year risk of sudden cardiac death (low <4%, intermediate 4–6%, high >6%). This risk prediction model is currently undergoing validation in other independent HCM cohorts.

Genetic Testing in HCM

HCM Disease Genes

Familial HCM is a genetically heterogeneous disorder, meaning a mutation in more than one gene can lead to the same condition. At least 11 causative genes have been identified to date, which primarily encode  sarcomere or sarcomere-related proteins, and include the cardiac b-myosin heavy chain (MYH7), myosin binding protein C (MYBPC3), cardiac troponin T, tropomyosin, cardiac troponin I, essential and regulatory myosin light chain, and more recently, titin and actinin-2 genes [6]. A single mutation in any of these genes will lead to HCM. Most recently, multiple mutations in the one individual (i.e. two or three gene mutations) have been iden- tified, and these individuals may develop clinically more severe disease [7,8].

Genetic Testing

Genetic testing for HCM is used to identify the disease- causing gene mutation.  This genetic information can be used for cascade genetic testing in at-risk family members, and can therefore facilitate earlier management of at-risk members and avoid lifetime clinical surveillance in those family members who have a negative predictive genetic test [9]. Genetic testing may also assist in making future repro- ductive decisions, since a known gene mutation in the family can be used in preimplantation genetic diagnosis


278                                                                                                                                                                                                    C. Semsarian

 

(PGD), as well as in antenatal testing. Current testing sug- gests that screening of the 10 most common HCM-causing genes results in a gene-positive pick-up rate of 40–50%. This pick-up rate increases to 70–80% if there is a definite family history of HCM [10]. All patients need to undergo genetic counselling prior to genetic testing, and genetic testing in HCM is best undertaken in the setting of a specialised multidisciplinary clinic [11].

Management of HCM

Affected Individuals

Major advances have been made in the management of patients with HCM in the last 5 years [3]. The clinical man- agement of HCM however remains complex, in part due to the heterogeneous symptoms exhibited by affected individ- uals as well as the marked variability in the natural history of this disease. Hypertrophic cardiomyopathy can occur with- out symptoms, but many individuals experience some dys- pnoea, angina and palpitations. The natural history of the disease is usually a gradual progression of symptoms, but in some, sudden death or severe heart failure is superimposed. Sudden death occurs most commonly in HCM either during or immediately after exercise, although death can also occur at rest.

Many treatment options are currently available for HCM patients. This ranges from no treatment; lifestyle modifica- tions, e.g. avoiding competitive sports in all patients with HCM; use of pharmacological agents e.g. beta blockers, cal- cium channel blockers, and diuretics; to surgical septal myec- tomy and transcoronary alcohol septal ablation of the myocardium (i.e. the creation of a limited septal infarct by direct injection of alcohol into a septal perforator artery) for individuals with significant left ventricular outflow tract obstruction with symptoms unresponsive to drug therapy. The single most important advance in the clinical manage- ment of HCM has involved the use of ICD therapy in the prevention of sudden death [12]. Recent studies indicate that treatment of individuals at highest risk of sudden death with an ICD is the most definitive form of therapy in preventing sudden death and easily surpasses empirically-based pre- ventative strategies previously used in HCM, e.g. amiodar- one and beta blockers.

Asymptomatic Family Members

It is strongly recommended that all first-degree relatives of an affected individual be clinically screened for HCM. As a minimum, this involves a physical examination by a cardiol- ogist, an ECG and a transthoracic echocardiogram. Cardiac magnetic resonance imaging is also emerging as an impor- tant investigation in the initial evaluation of HCM patients. The suggested time intervals for clinical screening of unaf- fected family members is shown in Table 2 but should be individually tailored to each person. Clinical screening in children under age 12 years is variable, and depends on clinical  circumstances,  including  family  history.  Clinical surveillance remains lifelong, although the frequency of screening is less frequent in older age groups. Screening of second-degree relatives should be decided in a family-by- family basis, and depends on a variety of factors including severity of disease in the family, outcomes from screening the first-degree relatives, the family member’s desire, and clini- cal judgement.

Family History and Genetic Counselling

Genetic counselling for patients with HCM is essential. In all cases it is important that a detailed family history is taken. Particular attention to age and circumstances of a family member’s death, as well as retrieving any medical records or postmortem reports can provide valuable information when determining if a death was attributed to HCM. As mentioned, a family history of sudden cardiac death is a major risk factor for patients.

The inheritance of HCM should be clearly explained. This will give patients a good understanding of the risk of passing on the disorder to children and highlight the importance of clinically screening family members. If a genetic mutation is identified in the family, genetic counselling is strongly advised before family members undergo preclinical genetic testing [13]. The advantages and disadvantages of a genetic result must be fully understood before a decision about testing should be made.

Future Perspectives

While significant advances have been made in our under- standing of the pathogenesis of HCM, the genetic causes, and in the development of new approaches to diagnosis, treat- ment, and prevention, many clinical issues remain unre- solved and will be a focus for research efforts in the coming years. These areas include defining the cause of HCM in all patients, the emergence of genotype positive-phe- notype negative HCM patients (so-called HCM ‘‘silent gene carriers”), improving risk stratification algorithms for sud- den death, further understanding the role of myocardial fibrosis in the development and progression of HCM, and developing novel therapies to treat HCM and its complications.


Hypertrophic Cardiomyopathy                                                                                                                                                                     279

Further  Information

For further information about this document, please contact Professor Christopher Semsarian, Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, Locked Bag 6, Newtown NSW 2042 Australia; c.semsarian@centenary.  org.au

Acknowledgements

This document was reviewed and edited by the following members of the Genetic Council of the Cardiac Society of Australia and New Zealand: Drs John J Atherton and Mark Ryan. We are grateful to Charlene Nell for her work in preparing the manuscript for publication.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.hlc.2017. 10.007.

References

[1] Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124:2761–96.

[2] Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733–79.

[3] Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 2014;64:83–99.

[4] Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 2015; 65:1249–54.

[5] O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 2014; 35:2010–20.

[6] Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomy- opathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012;60

:705–15.

[7] Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C. Com- pound and double mutations in patients with hypertrophic cardiomy- opathy: implications for genetic testing and counselling. J Med Genet 2005;42:e59.

[8] Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm 2012; 9:57–63.

[9] Ingles J, Semsarian C. The value of cardiac genetic testing. Trends Cardiovasc Med 2014;24:217–24.

[10] Ingles J, Sarina T, Yeates L, Hunt L, Macciocca I, McCormack L, et al. Clinical predictors of genetic testing outcomes in hypertrophic cardio- myopathy. Genet Med 2013;15:972–7.

[11] Ingles J, Semsarian C. Conveying a probabilistic genetic test result to families with an inherited heart disease. Heart Rhythm 2014;11:1073–8.

[12] Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:405–12.

[13] Ingles J, Yeates L, Semsarian C. The emerging role of the cardiac genetic counselor. Heart Rhythm 2011;8:1958–62.

Leave a Comment